Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868803 · ClinicalTrials.gov registry record
Aberrant Gene Expression Prostate Carcinoma
A clinical trial of Prostate Cancer, sponsored by Lahey Clinic.
- Active
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT00868803 is a study of Prostate Cancer that is active but no longer recruiting, run by Lahey Clinic. The registered enrollment target is 5,000 participants, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00868803, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Lahey Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
Conditions Studied
Study Locations (1)
Massachusetts
- Lahey Clinic - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 1995-04 |
| Est. Completion | 2030-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868803
The ClinicalTrials.gov registry entry for NCT00868803 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00868803 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00868803 about?
NCT00868803 is a clinical study titled "Aberrant Gene Expression Prostate Carcinoma". The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
What is the current status of trial NCT00868803?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 1995-04. Estimated completion is 2030-04.
What conditions does trial NCT00868803 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT00868803?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00868803 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.